PTAB statistics

PTAB Trial Statistics as of February 5, 2015

As of February 5, 2015, USPTO records show 2,757 AIA trial petitions filed since September 16, 2012 (2,451 IPR, 296 CBM, 4 PGR, 6 derivation). The Board had instituted trial on 1,223 petitions and denied 603 (67.0% instituted) and had issued 278 final written decisions. In fiscal year 2015 to that date, 676 petitions were filed.

Key Facts

As of
February 5, 2015
Fiscal year
FY2015
Petitions filed (cumulative)
2,757
Institution rate (cumulative)
67.0%
Petitions filed (FY2015 to date)
676
Data retrieved
October 31, 2026
On this page
  1. Cumulative Figures as of February 5, 2015
  2. Fiscal Year 2015 to Date
  3. Change Since January 1, 2015
  4. Trial Types Covered
  5. How These Figures Were Compiled
  6. Related Statistics

This page gives Patent Trial and Appeal Board trial figures as of February 5, 2015, which falls in fiscal year 2015 (October 1, 2014 to September 30, 2015). The cumulative figures run from September 16, 2012, when AIA trials began. The full year is covered on the FY2015 statistics page.

Cumulative Figures as of February 5, 2015

Events from September 16, 2012 to February 5, 2015, by trial type:

MeasureIPRPGRCBMDERTotal
Petitions filed2,451429662,757
Institution decisions: instituted1,093013001,223
Institution decisions: denied5292693603
Institution rate (by petition)67.4%0.0%65.3%0.0%67.0%
Final written decisions2450330278
Terminations without a final written decisionCount
Settlements251
Adverse judgment0
Dismissed0
Other terminations9

Fiscal Year 2015 to Date

Events from October 1, 2014 to February 5, 2015:

MeasureIPRPGRCBMDERTotal
Petitions filed6102631676
Institution decisions: instituted3540230377
Institution decisions: denied1762130191
Institution rate (by petition)66.8%0.0%63.9%—66.4%
Final written decisions950160111
Terminations without a final written decisionCount
Settlements107
Adverse judgment0
Dismissed0
Other terminations1

Change Since January 1, 2015

Between the previous dated page (January 1, 2015) and February 5, 2015, 172 petitions were filed, 95 trials were instituted, 61 petitions were denied institution and 33 final written decisions issued. The cumulative institution rate moved from 67.5% to 67.0%.

Trial Types Covered

2,451 of the 2,757 petitions (88.9%) were for inter partes review, which challenges patent claims on prior-art grounds under 35 U.S.C. chapter 31. The remainder were for covered business method review (296), post-grant review under chapter 32 (4) and derivation proceedings (6). Institution standards differ by proceeding; see the threshold standards.

How These Figures Were Compiled

The figures are counted from USPTO Open Data Portal records retrieved on October 31, 2026, keeping only events dated on or before February 5, 2015: a petition by its filing date, an institution decision by its decision date, and a final written decision or termination by its date. They are a reconstruction from the current records, not the USPTO’s report of that date, and may differ from statistics the USPTO published at the time. Final written decision outcomes are not reported because the records state them for too few decisions. The methodology gives the counting rules in full.

Frequently Asked Questions

How many AIA trial petitions had been filed as of February 5, 2015?

USPTO records show 2,757 petitions filed from September 16, 2012 to February 5, 2015: 2,451 IPR, 296 CBM, 4 PGR and 6 derivation.

What was the PTAB institution rate as of February 5, 2015?

Cumulatively, 67.0% by petition: 1,223 instituted and 603 denied. In FY2015 to that date the rate was 66.4%.

Primary Sources

  1. USPTO Open Data Portal (PTAB trial proceedings and decisions data)
  2. USPTO Patent Trial and Appeal Board statistics
  3. 35 U.S.C. chapter 31 (inter partes review)
  4. 35 U.S.C. chapter 32 (post-grant review)
  5. 37 C.F.R. Part 42 (trial practice before the PTAB)

Educational information; not legal advice. Statutes, rules and USPTO practice change. Confirm against the primary sources and consult a registered patent practitioner before acting. Disclaimer.